00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:35 , Aug 8, 2017 |  BC Extra  |  Company News

Depomed plummets on reduced sales guidance

Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its...
21:49 , Jul 27, 2017 |  BC Innovations  |  Product R&D

Spheres of influence

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...
14:15 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Arthritis; pain Cell culture and mouse studies suggest a pyrazolopyridine-based GPR4 inhibitor could help treat arthritis or pain. Chemical synthesis of pyrazolopyridine analogs and testing in a human cell line yielded an oxadiazole-containing compound that...
07:00 , May 9, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/6 clsAcadia Pharmaceuticals Inc. (NASDAQ:ACAD)Leerink PartnersPaul MatteisDowngradeMarket perform (from outperform)-14%$27.65 Matteis also lowered his target to $35 from $40. He remains "confident in the value proposition of pimavanserin"...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Diclofenac: Clinical trial data

Top-line data from a double-blind, German trial in 126 patients with grade I or II ankle sprains showed that twice-daily topical Pennsaid 2% for 8 days missed the primary endpoint of reducing pain on movement...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Crescita, Nuvo Pharma drug delivery, inflammation, neurology news

Nuvo Pharmaceuticals (formerly Nuvo Research Inc.) spun out its drug development business into stand-alone company Crescita. Nuvo Pharmaceuticals will focus on its Pennsaid diclofenac franchise. Crescita is developing topical formulations of drugs for...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

Nuvo drug delivery, inflammation, neurology news

Nuvo said it plans to spin out its drug development business into a stand-alone, publicly traded company. Nuvo would become a profitable commercial company focused on its Pennsaid diclofenac franchise. The spinout would focus...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclooxygenase-2 (COX-2); 5-lipoxygenase (ALOX5; 5-LO)

Inflammation INDICATION: Inflammation; pain In vitro and mouse studies suggest an inhibitor of COX-2 and ALOX5 could treat pain and inflammation. Chemical synthesis of barbituric acid analogs followed by testing in COX-2 and ALOX5 assays identified a...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Iroko, Laboratorios Saval deal

Iroko granted Laboratorios Saval exclusive rights to develop and commercialize Zorvolex submicron diclofenac in Bolivia, Chile, Ecuador, Paraguay and Peru. Saval will be responsible for obtaining regulatory and pricing approval in the countries. Zorvolex...